-+ 0.00%
-+ 0.00%
-+ 0.00%

Biomea Fusion Q3 net loss narrows 62% to $6.18 million

PUBT·11/10/2026 21:11:54
Listen to the news
Biomea Fusion Q3 net loss narrows 62% to $6.18 million
  • Biomea Fusion’s third-quarter 2026 net loss narrowed 62% year over year to $6.18 million.
  • Research and development expenses fell 41% year over year to $8.53 million.
  • Cash, cash equivalents and restricted cash totaled $26.77 million at September 30, with runway projected into the second quarter of 2027.
  • Enrollment finished in Phase II COVALENT-211 evaluating icovamenib for insulin-deficient type 2 diabetes; topline data are expected in first-quarter 2027.
  • COVALENT-212 enrollment remains ongoing for patients missing glycemic targets on GLP-1-based therapy, with topline data expected in second-quarter 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomea Fusion Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611101605PRIMZONEFULLFEED9874118) on November 10, 2026, and is solely responsible for the information contained therein.